PMID- 37062839
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230419
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Apr 16
TI  - Antioxidants-related nuclear factor erythroid 2-related factor 2 gene variants 
      associated with HBV-related liver disease.
PG  - 72
LID - 10.1186/s12935-023-02918-6 [doi]
LID - 72
AB  - BACKGROUND: Accumulating evidence demonstrated that nuclear factor erythroid 
      2-related factor 2 (NRF2) expression plays a crucial role in the proliferation, 
      invasion and metastasis of hepatocellular carcinoma (HCC). However, research on 
      the effect of NRF2 genetic polymorphism on the development of chronic hepatitis B 
      (CHB), HBV-related liver cirrhosis (LC) and HCC is still missing. METHODS: A 
      total of 673 individuals were included in the study and classified into four 
      groups: 110 CHB cases, 86 LC cases, 260 HCC cases, and 217 healthy controls. ​The 
      polymerase chain reaction-restriction fragment length polymorphism and DNA 
      sequencing method were used to detect rs6721961 and rs6726395 polymorphisms. 
      RESULTS: Patients carrying the T allele in rs6721961 were at a higher risk of HCC 
      than individuals with the G allele compared to CHB patients (OR = 1.561, 95%CI: 
      1.003-2.430, P = 0.048). The statistically significant differences were also 
      found in the rs6721961 GT genotype (OR = 2.298, 95% CI: 1.282-4.119, P = 0.005) 
      and dominant model (OR = 2.039, 95% CI: 1.184-0.510, P = 0.010). Subgroup 
      analysis also detected a significant association between the rs6721961 T allele 
      and the development of HCC in older subjects (>/= 50 years) (OR = 2.148, 95% CI: 
      1.208-3.818, P = 0.009). Statistical analysis results indicated that subjects 
      carrying haplotype G-A had a lower risk of HCC (OR = 0.700, 95% CI: 0.508-0.965, 
      P = 0.028). CONCLUSIONS: For the first time, our findings provide evidence that 
      the NRF2 gene rs6721961 variation is a potential genetic marker of susceptibility 
      to HCC.
CI  - (c) 2023. The Author(s).
FAU - Liu, Yanqiong
AU  - Liu Y
AD  - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of 
      Education, Department of Clinical Laboratory, The First Affiliated Hospital of 
      Guangxi Medical University, Nanning, Guangxi, China.
FAU - Wu, Qiulian
AU  - Wu Q
AD  - Department of Clinical Laboratory, The People's Hospital of Guangxi Zhuang 
      Autonomous Region, Nanning, Guangxi, China.
FAU - Zhang, Fuyong
AU  - Zhang F
AD  - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of 
      Education, Department of Clinical Laboratory, The First Affiliated Hospital of 
      Guangxi Medical University, Nanning, Guangxi, China.
FAU - Qin, Xue
AU  - Qin X
AD  - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of 
      Education, Department of Clinical Laboratory, The First Affiliated Hospital of 
      Guangxi Medical University, Nanning, Guangxi, China. qinxue919@126.com.
LA  - eng
GR  - Z20210158/Self-financing Scientific Research Subject of Guangxi Health 
      Department/
PT  - Journal Article
DEP - 20230416
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC10105925
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Nuclear factor erythroid 2-related factor 2
OT  - Polymorphism
COIS- The authors confirm that there are no conflicts of interest.
EDAT- 2023/04/17 06:00
MHDA- 2023/04/17 06:01
PMCR- 2023/04/16
CRDT- 2023/04/16 23:43
PHST- 2023/02/14 00:00 [received]
PHST- 2023/04/03 00:00 [accepted]
PHST- 2023/04/17 06:01 [medline]
PHST- 2023/04/16 23:43 [entrez]
PHST- 2023/04/17 06:00 [pubmed]
PHST- 2023/04/16 00:00 [pmc-release]
AID - 10.1186/s12935-023-02918-6 [pii]
AID - 2918 [pii]
AID - 10.1186/s12935-023-02918-6 [doi]
PST - epublish
SO  - Cancer Cell Int. 2023 Apr 16;23(1):72. doi: 10.1186/s12935-023-02918-6.